Replies to post #481253 on NorthWest Biotherapeutics Inc (NWBO)

[Kaizenman]

Lykiri: Awesome find as usual!

This is setting up quite the quandry for treatment decision making. We have this study saying that Chemo likely causes trait changes, and this same thing might be causing the PIII results to appear starkly different.

Chemo will always be needed to abate tumor growth in acute brain/organ regions, but not only does Chemo have the horrible side effects, it now appears it actually can make the recurrent cancer change to the worse.

I think the new SOC will be to not use Chemo or at least delay its use as long as possible.

Thanks!

[flipper44]

Thanks Lykiri.

Found this interesting:

Although other microenvironmental changes were limited, myeloid (innate immune) cell states may play a role in tumor response to treatment, including driving a transition toward the mesenchymal subtype. Thorough characterization of tumor-myeloid interactions and other factors involved, if any, will allow for accurate forecasting of phenotype at recurrence, again guiding therapy choices.

[flipper44]

Lykiri, here is another interesting paper from March 2021.

https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01151-4

Thus, the focus of our review will be on the recent advances in the understanding of the transcriptome of mesenchymal GBM and discuss microenvironmental, metabolic, and treatment-related factors as critical components through which the mesenchymal signature may be acquired. We also take into consideration the transcriptomic plasticity of GBM to discuss the future perspectives in employing selective therapeutic strategies against mesenchymal GBM.

Among the identified transcriptional subtypes, the mesenchymal subtype has been found associated with more aggressive, invasive, angiogenic, hypoxic, necrotic, inflammatory, and multitherapy-resistant features than other transcriptional subtypes. Accordingly, mesenchymal GBM patients were found to exhibit worse prognosis than other subtypes when patients with high transcriptional heterogeneity were excluded.